J&J Unlikely To Cut Risperdal Deals As Appeals Play Out
Even after four losses — including a recent $70 million verdict — and another trial opening this week, attorneys say Johnson & Johnson is unlikely to consider settling thousands of pending...To view the full article, register now.
Already a subscriber? Click here to view full article